Hogan Lovells

Life Sciences (International Firms) Department

China
Current View:

This content is provided by Hogan Lovells.

Overview

In this highly regulated, complex industry, clients need a legal advisor that truly understands the life sciences and healthcare sector. Hogan Lovells is one of very few practices that can offer this in China along with the ability to advise on the full scope of life sciences issues – from initial clinical trials to off-patent strategy, and from business development to defending complex
litigation.

They have a strong China regulatory practice and help their life sciences clients navigate complex regulatory hurdles. They have an incredibly strong regulatory practice comprising of partners who have previously worked in government and thus understand the ins and outs of the regulation. They also stay on top of innovation in the industry and how it is regulated such as wearable technology,
digital health, biosimilars and big data. 

They represent some of the biggest names in this sector. Globally, they have represented eight of the top 10 biotech companies, 19 of the top 20 pharmaceutical companies, and 29 of the top 30 medical devices companies in the world over the past year. These clients come to them because they are excellent at what they do and they trust the firm with their most business-critical and ground-breaking matters.

The team has strengths across all areas of law,including regulatory, pricing and reimbursement, commercial, IP and patent litigation, product liability as well as corporate/M&A and compliance and investigation.

Members

Chen, Eugene

Wei, Jun

Zou, Roy

Clients

3M

Helsinn

JW Therapeutics (Shanghai) Co., Ltd.

Novartis

Sanofi

Starr Companies

University of Miami

Valeant Pharmaceuticals

Industries

Food & Drink Producers

Health Care

Pharmaceuticals & Life Sciences

Technology, Hardware & Electronics

Telecommunications